FDA Working To Smooth Snags In Shared Clozapine REMS
This article was originally published in The Pink Sheet Daily
Physician registration deadline extended again as merger of six individual clozapine registries to shared REMS creates technical glitches.
You may also be interested in...
US FDA says pharmacists may dispense the antipsychotic without a REMS authorization and wholesalers may continue to ship it during temporary suspension of REMS. A high call volume and long wait times have impacted patient access since the modified REMS launched on 15 November.
Pfizer alleges its associate director of statistics transferred 12,000 files from her company laptop ahead of move to Xencor. Company seeks a temporary restraining order to prevent her from disclosing confidential information, including information on Pfizer’s COVID-19 vaccine and monoclonal antibodies for treatment of cancer.
Lilly’s Alzheimer’s Drug Will Get ‘Easier Ride’ Than Aduhelm But Does Not Show Clinical Benefit, Prof Says
Harsh assessment of Lilly’s Phase II study by UCL and UCSF professors suggests donanemab may face same hurdles as Biogen’s Aduhelm. Lilly exec says the drug slowed disease progression by six months, but UCL prof says that won’t make a difference.